Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

BackgroundElexacaftor/Tezacaftor/Ivacaftor (ETI) has demonstrated significant efficacy in enhancing clinical outcomes for patients with cystic fibrosis (CF). Despite this, comprehensive post-marketing assessments of its adverse drug events (ADEs) remain insufficient. This study aims to analyze the A...

Full description

Bibliographic Details
Main Authors: Chengyu Zhu, Zhiwei Cui, Tingting Liu, Siyu Lou, Linmei Zhou, Junyou Chen, Ruizhen Zhao, Li Wang, Yingyong Ou, Fan Zou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
CFTR modulator
pharmacovigilance
FAERS
real world analysis
adverse drug events
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1531514/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1531514/full

Similar Items